New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNonapeptide-1 vs Orforglipron

Nonapeptide-1 vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Nonapeptide-1
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
Not applicable (topical)
~12 hours (once-daily oral dosing)
Admin Route
Topical
Oral
Research
Typical Dose
0.05–0.5% concentration in formulation
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Twice daily
Once daily
Key Benefits
  • Inhibits UV-induced tanning and hyperpigmentation
  • Reduces hormonal melasma
  • Evens skin tone at receptor level
  • Well-tolerated with minimal irritation
  • Complementary to tyrosinase inhibitors for enhanced brightening
  • Reduces post-inflammatory hyperpigmentation
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Generally very well-tolerated
  • Rare contact sensitivity in susceptible individuals
  • Theoretical risk of excessive depigmentation with prolonged high-concentration use
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With